TUG1 and central nervous system cancer: For instance, the study conducted by Katsushima and his group on lncRNA TUG1 used antisense oligonucleotides delivered via drug delivery vehicles to target TUG1 in an in-vivo glioma model to repress glioma stem cells growth [203].